Please provide your email address to receive an email when new articles are posted on . BOSTON — Finerenone reduces CV and renal events in patients with type 2 diabetes and chronic kidney disease, and ...
Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes. However, ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Adults with type 2 diabetes and chronic kidney disease ...
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer’s Phase III cardiovascular outcomes study FIGARO-DKD, evaluating the efficacy and safety of the investigational drug finerenone versus placebo when added to ...
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that detailed results from the FIDELIO-DKD Phase III study demonstrated that the investigational drug finerenone slowed the progression of ...
Hosted on MSN
Finerenone shows superior survival and kidney protection over spironolactone in diabetic kidney disease
Researchers from National Taiwan University Hospital and collaborating institutions have demonstrated that finerenone, a new-generation nonsteroidal mineralocorticoid receptor antagonist (MRA), ...
In patients with type 2 diabetes and chronic kidney disease, diuretic use does not affect the safety and efficacy of finerenone. The safety and efficacy of finerenone is not affected by diuretic use ...
Compared with monotherapy, finerenone plus empagliflozin was associated with improved kidney outcomes in T2D and CKD regardless of GLP-1RA use. Compared with monotherapy and regardless of prior ...
Limited evidence exists to support the simultaneous initiation of sodium–glucose cotransporter-2 inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in persons with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results